Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

207 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial.
Solsona E, Madero R, Chantada V, Fernandez JM, Zabala JA, Portillo JA, Alonso JM, Astobieta A, Unda M, Martinez-Piñeiro L, Rabadan M, Ojea A, Rodriguez-Molina J, Beardo P, Muntañola P, Gomez M, Montesinos M, Martinez Piñeiro JA; Members of Club Urológico Español de Tratamiento Oncológico. Solsona E, et al. Among authors: martinez pineiro ja. Eur Urol. 2015 Mar;67(3):508-16. doi: 10.1016/j.eururo.2014.09.026. Epub 2014 Oct 6. Eur Urol. 2015. PMID: 25301758 Clinical Trial.
Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials.
Fernandez-Gomez J, Solsona E, Unda M, Martinez-Piñeiro L, Gonzalez M, Hernandez R, Madero R, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Isorna S, Rabadan M, Astobieta A, Montesinos M, Muntañola P, Gimeno A, Blas M, Martinez-Piñeiro JA; Club Urológico Español de Tratamiento Oncológico (CUETO). Fernandez-Gomez J, et al. Among authors: martinez pineiro l, martinez pineiro ja. Eur Urol. 2008 May;53(5):992-1001. doi: 10.1016/j.eururo.2007.10.006. Epub 2007 Oct 15. Eur Urol. 2008. PMID: 17950987
Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.
Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Piñeiro L, Gonzalez M, Portillo J, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Rabadan M, Astobieta A, Montesinos M, Isorna S, Muntañola P, Gimeno A, Blas M, Martinez-Piñeiro JA. Fernandez-Gomez J, et al. Among authors: martinez pineiro l, martinez pineiro ja. J Urol. 2009 Nov;182(5):2195-203. doi: 10.1016/j.juro.2009.07.016. Epub 2009 Sep 16. J Urol. 2009. PMID: 19758621
The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables.
Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Piñeiro L, Ojea A, Portillo J, Montesinos M, Gonzalez M, Pertusa C, Rodriguez-Molina J, Camacho JE, Rabadan M, Astobieta A, Isorna S, Muntañola P, Gimeno A, Blas M, Martinez-Piñeiro JA; Club Urológico Español de Tratamiento Oncológico. Fernandez-Gomez J, et al. Among authors: martinez pineiro ja. Eur Urol. 2011 Sep;60(3):423-30. doi: 10.1016/j.eururo.2011.05.033. Epub 2011 May 25. Eur Urol. 2011. PMID: 21621906
Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial.
Martínez-Piñeiro JA, Martínez-Piñeiro L, Solsona E, Rodríguez RH, Gómez JM, Martín MG, Molina JR, Collado AG, Flores N, Isorna S, Pertusa C, Rabadán M, Astobieta A, Camacho JE, Arribas S, Madero R; Club Urológico Español de Tratamiento Oncológico (CUETO). Martínez-Piñeiro JA, et al. Among authors: martinez pineiro l. J Urol. 2005 Oct;174(4 Pt 1):1242-7. doi: 10.1097/01.ju.0000173919.28835.aa. J Urol. 2005. PMID: 16145378 Clinical Trial.
A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.
Ojea A, Nogueira JL, Solsona E, Flores N, Gómez JM, Molina JR, Chantada V, Camacho JE, Piñeiro LM, Rodríguez RH, Isorna S, Blas M, Martínez-Piñeiro JA, Madero R; CUETO Group (Club Urológico Español De Tratamiento Oncológico). Ojea A, et al. Among authors: pineiro lm, martinez pineiro ja. Eur Urol. 2007 Nov;52(5):1398-406. doi: 10.1016/j.eururo.2007.04.062. Epub 2007 Apr 27. Eur Urol. 2007. PMID: 17485161 Clinical Trial.
Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
Martínez-Piñeiro L, Portillo JA, Fernández JM, Zabala JA, Cadierno I, Moyano JL, Solsona E, Unda M, Beardo P, Rodríguez-Molina J, Chantada V, Palou J, Muntañola P, Alonso Dorrego JM, Pérez-Garcia FJ, Silva JM, Chesa N, Montesinos M, Ojea A, Madero R, Martínez-Piñeiro JA. Martínez-Piñeiro L, et al. Among authors: martinez pineiro ja. Eur Urol. 2015 Aug;68(2):256-62. doi: 10.1016/j.eururo.2015.02.040. Epub 2015 Mar 18. Eur Urol. 2015. PMID: 25794457 Clinical Trial.
BCG update: intravesical therapy.
Martínez-Piñeiro JA, Martínez-Piñeiro L. Martínez-Piñeiro JA, et al. Among authors: martinez pineiro l. Eur Urol. 1997;31 Suppl 1:31-41. doi: 10.1159/000474529. Eur Urol. 1997. PMID: 9076484 Review.
207 results